Financial Performance - The company achieved a consolidated net profit attributable to shareholders of RMB 2,915,244,576.05 for the year 2020, with a base net profit of RMB 1,940,615,878.98, resulting in a 50.3% increase year-on-year [3]. - The company's operating revenue for 2020 was RMB 61,673,702 thousand, a decrease of 5.05% compared to RMB 64,951,778 thousand in 2019 [15]. - Net profit attributable to shareholders for 2020 was RMB 2,915,245 thousand, down 8.58% from RMB 3,188,885 thousand in 2019 [15]. - The basic earnings per share for 2020 was RMB 1.793, reflecting an 8.58% decrease from RMB 1.961 in 2019 [16]. - The total profit for 2020 was RMB 3,739.08 million, down 9.43% compared to the previous year [44]. - The company reported a significant increase in cash flow from financing activities, rising by 164.49% to RMB 1,439,376 thousand [48]. - The company's cash flow from operating activities for 2020 was RMB 585,185 thousand, a significant decrease of 88.35% compared to RMB 5,022,367 thousand in 2019 [15]. Dividend Distribution - The proposed cash dividend is RMB 5.38 per 10 shares, totaling RMB 874,675,530.56, with a distribution based on a total share capital of 1,625,790,949 shares [3]. - The retained earnings available for distribution at the end of 2020 amount to RMB 6,778,560,101.62 after accounting for the legal surplus reserve and previous year's dividends [155]. - The company has maintained a consistent dividend payout ratio, with 30.03% in 2019 and 20.03% in 2018 [156]. - The independent non-executive directors have expressed their opinions on the profit distribution plan, which is subject to approval at the annual general meeting [155]. Risk Management - The company does not foresee any significant risks that could materially impact its production and operations during the reporting period [5]. - The report emphasizes that future plans and development strategies do not constitute a substantive commitment to investors, highlighting the importance of investment risk awareness [5]. - The report covers various risks and countermeasures faced by the company in its operational processes, detailed in the discussion and analysis section [5]. - The company emphasizes the importance of risk management and internal controls to enhance its overall risk prevention capabilities [145]. Research and Development - The company is investing CNY 200 million in research and development for biopharmaceutical technologies, aiming for a 30% increase in R&D output [14]. - The company applied for 85 patents during the reporting period, including 71 invention patents and 14 utility model patents [47]. - The company has 5 national-level R&D institutions, 1 national-level enterprise technology center, and 16 provincial-level enterprise technology centers, showcasing a strong innovation system [43]. - The company's R&D investment for the reporting period amounted to RMB 618,859.48 thousand, representing 1.00% of operating revenue and 2.19% of net assets [128]. Market Expansion and Product Development - The company plans to expand its market presence by entering three new provinces in 2021, targeting a 10% market share in these regions [14]. - New product development includes the launch of five innovative drugs, expected to contribute an additional CNY 500 million in revenue over the next two years [14]. - The company is focusing on expanding its product offerings and enhancing its market presence through new product development and strategic entries into medical insurance catalogs [105]. - The company is actively participating in centralized drug procurement to optimize pricing and increase market share [108]. Compliance and Governance - The company is committed to maintaining compliance with Good Manufacturing Practice (GMP) standards to ensure product quality and safety [11]. - The company has committed to maintaining its independence post-major asset restructuring in 2013, ensuring compliance with relevant laws and regulations [158]. - The company is committed to complying with environmental regulations and enhancing management of environmental assessments for construction projects [99]. - The company has no significant related party transactions during the reporting period [184]. Acquisitions and Investments - The company completed the acquisition of the "Wanglaoji" trademark series from its controlling shareholder, Guangzhou Pharmaceutical Group, with the transaction approved on March 28, 2019 [166]. - The company purchased 30% equity of a pharmaceutical company for RMB 1,094 million in cash, with the transaction completed on May 31, 2018 [169]. - The company has the option to acquire an additional 20% equity in the pharmaceutical company within a specified period, which has not yet been exercised by the seller [169]. - The company has ongoing strategies for market expansion and product development, as indicated by the agreements and acquisitions made during the reporting period [196].

广州白云山医药集团股份有限公司 GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS COMPANY LIMITED 2020 年年度报告 2021 年 3 月 重要提示 （一）本公司董事会、监事会及董事、监事及高级管理人员保证本年度报告内容真 实、准确和完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别及连带的法 律责任。 （二）本公司全体董事出席了第八届第十次董事会会议，其中，董事长李楚源先生、 执行董事刘菊妍女士、执行董事兼总经理黎洪先生和独立非执行董事黄显荣先生以通讯 方式参加了会议。 （三）本集团与本公司截至 2020 年 12 月 31 日止年度之财务报告乃按中国企业会计 准则编制，经大信会计师事务所（特殊普通合伙）审计并出具了标准无保留意见审计报 告书。 （四）本公司董事长李楚源先生、执行董事兼总经理黎洪先生及财务副总监兼财务 部部长姚智志女士声明：保证本年度报告中财务报告真实、准确和完整。 （五）经董事会审议的本报告期利润分配预案或公积金转增股本预案 经大信会计师事务所（特殊普通合伙）审计确认：2020 年度本集团实现归属于本公 司股东的合并净利润人民 ...

廣 州白雲山医药集团股份有限公司 guangzhou baiyunshan pharmaceutical holdings co., ltd. (於中華人民共和國註冊成立之股份有限公司) (H股股份代碼：00874) (HWI 中期報告 重要提示 （一） 本公司董事會、監事會及其董事、監事、高級管理人員保證本半年度報告內容的真實、準確、完 整，不存在虛假記載、誤導性陳述或者重大遺漏，並承擔個別和連帶的法律責任。 （二） 本公司董事出席了第八屆董事會第四次會議，其中，執行董事兼總經理黎洪先生和執行董事兼常務 副總經理吳長海先生因公務未能親自出席會議，分別委託執行董事兼副總經理張春波先生和執行董 事劉菊妍女士代為出席並行使表決權；獨立非執行董事黃顯榮先生以通訊方式參加了會議。 （三） 本公司董事長李楚源先生、執行董事兼總經理黎洪先生及財務副總監兼財務部部長姚智志女士聲明： 保證本半年度報告中財務報告的真實、準確、完整。 （四） 經本公司董事會會議審議，本公司董事會建議不派發截至2020年6月30日止六個月之中期股息，亦 不進行公積金轉增股本。 （五） 本集團與本公司本報告期之財務報告乃按中國企業會計準則編製，未經 ...

广州白云山医药集团股份有限公司 GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS COMPANY LIMITED 2020 年半年度报告 2020 年 8 月 1 重要提示 （一）本公司董事会、监事会及其董事、监事、高级管理人员保证本半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律 责任。 （二）本公司董事出席了第八届董事会第四次会议，其中，执行董事兼总经理黎洪先生 和执行董事兼常务副总经理吴长海先生因公务未能亲自出席会议，分别委托执行董事兼副总 经理张春波先生和执行董事刘菊妍女士代为出席并行使表决权；独立非执行董事黄显荣先生 以通讯方式参加了会议。 （三）本公司董事长李楚源先生、执行董事兼总经理黎洪先生及财务副总监兼财务部部 长姚智志女士声明：保证本半年度报告中财务报告的真实、准确、完整。 （四）经本公司董事会会议审议，本公司董事会建议不派发截至 2020 年 6 月 30 日止六 个月之中期股息，亦不进行公积金转增股本。 （五）本集团与本公司本报告期之财务报告乃按中国企业会计准则编制，未经审计。 （六）本半年度报告中 ...

廣州白雲山医药集团股份有限公司 guangzhou baiyunshan pharmaceutical holdings co., ltd. (股份代號：0874) (HWL 更意了 年報 2019 目錄 | --- | --- | --- | |---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|---------| | | | | | 第一節 | 釋義 ......................................................................... | 3 | | 第二節 | 公司簡介和主要財務指標 ......................................................... | 8 | | 第三節 | 公司業務概 ...